<DOC>
	<DOCNO>NCT00750633</DOCNO>
	<brief_summary>The purpose study determine otic formulation safe effective treatment acute otitis externa ( AOE ) .</brief_summary>
	<brief_title>A Phase III Study Otic Formulation Acute Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Clinical diagnosis AOE base clinical observation presume bacterial origin A minimum combine score â‰¥4 least 1 affected ear Day 1 exam tenderness , erythema , edema Other protocoldefined inclusion criterion may apply Duration pretherapy sign symptom AOE great four ( 4 ) week Presence tympanostomy tube perforate tympanic membrane treat ear ( ) . Patients history tympanic membrane perforation enrol unless absence current perforation confirm Visit 1 prior enrollment Clinically diagnose chronic suppurative otitis medium , acute otitis medium , acute otorrhea patient tympanostomy tube , malignant otitis externa Known suspect ear infection fungal mycobacterial origin Prior otologic surgery within 6 month study entry Seborrheic dermatitis skin condition external auditory canal Current prior history immunosuppressive disorder ( e.g. , HIV positive ) current immunosuppressive therapy ( e.g. , cancer chemotherapy ) know acute chronic renal disorder active hepatitis Diabetic patient ( control uncontrolled ) base upon assessment Investigator Any systemic disease disorder , complicate factor structural abnormality would negatively affect conduct outcome study [ e.g. , cleft palate ( include repair ) , Downs Syndrome , cranial facial reconstruction ] Any current know suspected infection ( AOE ) require systemic antimicrobial therapy Use prohibit medication inadequate washout medication list protocol Concomitant use topical oral analgesic ( i.e. , NSAIDs aspirin product ) may anti inflammatory effect . Patients low dose aspirin therapy ( 81 mg per day ) time enrollment may enrol continue low dose aspirin study . Use acetaminophen ( `` Tylenol '' ) permit trial Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>swimmer 's ear</keyword>
	<keyword>ear drop</keyword>
	<keyword>ear infection</keyword>
	<keyword>ear pain</keyword>
	<keyword>ear inflammation</keyword>
</DOC>